# Hims review 2026: the public-company branded play, examined

> Source: https://peptidewellnessusa.com/providers/hims/
> Provider review · Premium DTC (public) · 2026
> By PeptideWellness Editorial Team · Updated November 11, 2026

Hims is a publicly traded telehealth platform (NYSE: HIMS) that has pivoted almost entirely from compounded GLP-1 to FDA-approved branded medications — Wegovy, Zepbound, Foundayo, Ozempic — sourced via manufacturer-direct partnerships with Novo Nordisk and Eli Lilly. The pivot worked: Novo Nordisk dropped its lawsuit against Hims in March 2026 after a partnership deal. Its named advisers check out in the NPI Registry, it has been BBB-accredited since 2018 (BBB currently gives it no letter grade), and the headline weight-loss claim is footnoted to a peer-reviewed Lancet paper. We pulled the live pricing matrix, verified the named medical leaders against the NPI Registry, weighed the two-tier pricing structure honestly, and read the November 2026 FTC privacy-and-billing complaint and the Q3 10-Q that answers it.

**The short version.** Hims is the men's-side product of Hims & Hers Health, Inc. (NYSE: HIMS) — the only publicly traded telehealth platform in our set. The company has pivoted heavily away from compounded GLP-1 and toward FDA-approved branded medications via manufacturer-direct partnerships with Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Foundayo) — and the pivot has produced a meaningful institutional outcome: **Novo Nordisk filed and then dropped a lawsuit against Hims in early 2026 as part of a new partnership deal**, settling the compounded-semaglutide dispute through commercial agreement rather than litigation.

The Better Business Bureau has listed Hims & Hers as accredited since 2018; it currently shows no letter grade. Four of the foregrounded doctors on the home page check out in the NPI Registry. The headline outcome claim is footnoted to a peer-reviewed Lancet paper rather than a self-published retrospective.

The main trade-offs are that "from $149/mo" understates the all-in cost once the $149/mo membership is added, that the same molecule (tirzepatide) appears at both $299/mo and $1,899/mo on the same page without plain-language explanation, that the compounded Hair Hybrids products mix into the same product grid as FDA-approved finasteride, that Trustpilot satisfaction is low at 2.9/5 over 9,743 reviews, and that the **Federal Trade Commission and seven states are suing the company** over its privacy, billing and cancellation practices — an amended complaint added five of those states on 10 November 2026, Hims has moved to dismiss, and it has set aside about $60 million against the case. Nothing in that suit concerns the safety of the medicines; the billing and cancellation allegations do concern the part of the service a customer meets. Best if you want branded FDA-approved GLP-1 with a named advisory layer; skip it if you are paying out of pocket and compounded GLP-1 at a lower monthly price is what you are after.

> "The only publicly traded provider in our set, with Tier A trials end-to-end on the headline weight-loss claim, BBB accreditation since 2018 and both manufacturer disputes now settled into partnerships — and, in the same filings that make all of that checkable, an FTC case over privacy and billing with about $60 million set aside against it." — Editorial on Hims

## What Hims is

Hims is the men's-focused brand of Hims & Hers Health, Inc., a public company trading on the New York Stock Exchange under the ticker HIMS. The company filed its 2017 SEC paperwork as a special-purpose acquisition target, then became publicly traded in early 2021 through a SPAC merger with Oaktree Acquisition Corp. The corporate entity is incorporated in Delaware, headquartered at 2269 Chestnut St in San Francisco, and reports against a calendar fiscal year. The most recent annual report (Form 10-K for fiscal year 2025) was filed with the SEC on 23 February 2026. SEC filings are the authoritative source for any quantitative claim about the company.

The platform was founded in November 2017 by Andrew Dudum (CEO), Jack Abraham, and Hilary Coles — Hims initially launched as a men's-side product addressing erectile dysfunction and hair loss, with Hers following in 2018. The company expanded into mental health and weight loss subsequently, and as of June 2025 self-reports 2.4M+ subscribers across the platform and a network of 400+ U.S.-licensed healthcare providers. The corporate Hims & Hers structure separates Hims (men) from Hers (women, on forhers.com); this review covers the men's surface only.

The product range is wide. Hims covers weight loss (FDA-approved GLP-1s primarily — Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro), sexual health (sildenafil and tadalafil generics plus branded Viagra and Cialis), hair regrowth (a mix of FDA-approved oral finasteride and oral minoxidil alongside compounded "Hair Hybrids"), mental health (sertraline, escitalopram), testosterone support (enclomiphene and supplements), and lab testing (a 130+ biomarker panel plus a multi-cancer signal test).

The defining strategic move of the past 18 months is the **GLP-1 pivot**. As the FDA's enforcement timeline closed in on mass-compounding of semaglutide and tirzepatide (see section 06), Hims aggressively repositioned toward branded manufacturer-direct partnerships — NovoCare Pharmacy for Wegovy and Ozempic, LillyDirect for Zepbound and Foundayo. The current GLP-1 menu is **almost entirely FDA-approved branded**, which is structurally different from the compounded-DTC providers covered elsewhere in our set.

## Pricing — and the catch

Hims's weight-loss pricing is multi-layered. There are two cost components — a membership fee and a separate medication fee — and within each medication there are two tiers: a partner-pricing tier (via LillyDirect or NovoCare) and a full-retail tier. The membership fee has a first-month promo and a recurring rate, and the medication "From $X/mo" labels in the page hero footnote into specifics that move the number meaningfully.

> Prices checked against the live /weight-loss page on 7 October 2026. Hims iterates on this pricing structure frequently — new oral GLP-1 formats were added in 2026 — so re-verification before signup is warranted. We update this page when prices change.

**Hims Weight Loss Membership (required for any GLP-1 medication)**

| Plan | Price |
| --- | --- |
| First month | **$39** (substantial discount from recurring) |
| Recurring | **$149/month**, auto-renew |

Page footnote: *"An active Hims Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership."*

**Medication pricing — on top of the membership fee, per month, if prescribed**

| Medication | Format | Price | FDA-approved for |
| --- | --- | --- | --- |
| Wegovy® Pill (oral semaglutide) | Oral | From $149/mo | Chronic weight management |
| Wegovy® Pill Microdosing Plan | Oral | From $149/mo | Chronic weight management |
| Wegovy® Pen (semaglutide SC) | Injection | From $199/mo | Chronic weight management |
| Zepbound® Vial (tirzepatide) | Injection (LillyDirect) | From $299/mo | Chronic weight management |
| Zepbound® KwikPen® | Injection (LillyDirect) | From $299/mo | Chronic weight management |
| Foundayo™ Pill (orforglipron) | Oral | From $149/mo | Chronic weight management (2025 approval) |
| Ozempic® Pill | Oral | From $149/mo | Type 2 diabetes only |
| Ozempic® (injectable) | Injection | From $199/mo | Type 2 diabetes only |
| **Mounjaro® (tirzepatide branded)** | Injection (full retail) | **$1,899/mo** | Type 2 diabetes only |
| **Zepbound® (branded full retail)** | Injection (full retail) | **$1,899/mo** | Chronic weight management |

**The two-tier same-molecule pricing.** The same drug — tirzepatide — appears on the Hims page at $299/month (Zepbound Vial or KwikPen, via the LillyDirect partner-pricing program) and at $1,899/month (branded Zepbound or Mounjaro through full retail). The six-fold gap reflects Eli Lilly's direct-to-consumer pricing program versus standard retail-pharmacy self-pay. Both are real prices, but the page does not explain the reason for the gap in plain language — the patient has to know about LillyDirect to understand why one tirzepatide is $299 and the other is $1,899. This isn't dishonest, but it isn't transparent either.

**All-in monthly cost example.** A patient on Wegovy Pen pays $39 (first-month membership) + $199 (medication) = **$238 first month**, then $149 + $199 = **$348/mo thereafter**. For Zepbound Vial via LillyDirect: $39 + $299 = **$338 first month**, then $149 + $299 = **$448/mo thereafter**. For full-retail Mounjaro: $149 + $1,899 = **$2,048/mo**. The "From $149/mo" footnote on the page hero is the lowest medication price (Wegovy Pill, Foundayo Pill, or Ozempic Pill) — patients who walk away with just that number in their head will be substantially mispriced.

**Insurance / FSA / HSA.** Hims's FAQ recommends using a credit/debit card and submitting for FSA/HSA reimbursement rather than running the FSA/HSA card directly at checkout. Insurance is not accepted.

## How the process works

The funnel is the standard cash-pay-telehealth template, with two distinctive features that follow from the public-company posture and the scale of the provider network.

**Online intake.** Detailed questionnaire covering symptoms, history, and treatment goals. Identity verification is required. The intake dynamically expands based on answers.

**Provider review.** A licensed provider on the Hims & Hers platform reviews the intake. Care is **asynchronous by default** — secure messaging back-and-forth rather than a live video or phone call — except in states that require live audio or video. This is structurally different from competitors who require synchronous video. The async model is genuinely faster for many patients but reduces depth of provider interaction.

**Pharmacy fulfillment.** Per the company's strategic pivot, the bulk of weight-loss medications now ship via manufacturer-direct programs (NovoCare Pharmacy for Novo Nordisk products, LillyDirect for Eli Lilly products). Compounded products in other categories (Hair Hybrids, custom Rx skincare, enclomiphene-based testosterone support) ship via partner compounding pharmacies. [Hims's terms](https://www.hims.com/terms-and-conditions "Source — Hims, Terms and Conditions, read 24 September 2026") name six pharmacies — Apostrophe Pharmacy, XeCare, EHT Pharmacy dba Curexa, CD Pharmacy dba Red Rock Pharmacy, AnazaoHealth and Strive Specialties — and say a prescription may be transferred between them.

**Shipping.** Discreet packaging, free shipping included.

**Ongoing care.** Unlimited messaging with the care team through the Hims app or web portal. The company also operates a proprietary AI/ML decision-support tool called MedMatch (launched 2023), described as helping providers consider treatment options drawn from de-identified platform interaction data. MedMatch is a company-stated capability; there is no peer-reviewed independent validation of its clinical impact.

## Does it work

Hims's outcome claims are notably better-sourced than the compounded-DTC competitors we've reviewed. The headline weight-loss claim on the /weight-loss page, as of our June 2026 check, was **"Lose up to 25% body weight"** with a footnote to [Lancet Diabetes & Endocrinology 2025](https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2825%2900226-8/abstract "Source — Lancet Diabetes & Endocrinology 2025, S2213-8587(25)00226-8") — the STEP UP trial of semaglutide 7.2 mg/wk, an investigational higher-dose protocol. This is a real peer-reviewed primary trial in a top-tier journal, which is the appropriate evidence base for that magnitude of weight loss.

For standard-dose semaglutide, the relevant trial remains [STEP 1](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 "Source — Wilding JPH et al., STEP 1, NEJM 2021, PMID 33567185"), which found adults with overweight or obesity lost on average **14.9% of body weight at 68 weeks** on once-weekly 2.4 mg semaglutide, versus ~2.4% on placebo. For tirzepatide, the [SURMOUNT-1 trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 "Source — Jastreboff AM et al., SURMOUNT-1, NEJM 2022") showed larger average losses — into the 20%+ range at the higher doses over 72 weeks. Wegovy's cardiovascular benefit, expanded by the FDA in March 2024, is supported by the SELECT trial (n=17,604, NEJM 2023). Hims's marketing references SELECT explicitly.

A material caveat for hair products: while Hims's oral finasteride and oral minoxidil are FDA-approved (Propecia 1997 and Rogaine 1988 respectively), the "Hair Hybrids" line — topical finasteride + minoxidil sprays, serums, and chewables — are **compounded products** that are not FDA-approved. Hims discloses this on the hair-loss page in standard language. The active ingredients are well-evidenced at standard doses, but the specific compounded formulations Hims dispenses are not the studied products.

A material limitation for the AI-assist layer: **MedMatch has no peer-reviewed independent validation**. Hims describes it as a tool that helps providers consider different treatment options; whether MedMatch-supported care produces better outcomes than provider judgment alone has not been studied in the published literature. The marketing reads as if MedMatch is a clinical capability; the evidence base is operational, not clinical.

## Safety and who should skip

GLP-1 therapy is a well-characterized drug class with a consistent side-effect profile. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea, mild digestive discomfort — typically most noticeable during dose escalation and often easing with time. Less common but more serious risks include pancreatitis and gallbladder problems. The FDA-approved branded GLP-1s carry a boxed warning based on rodent studies of thyroid C-cell tumors and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnancy is a contraindication. Hims's product pages link to drug-specific Important Safety Information for each medication (Wegovy, Zepbound, Foundayo, Ozempic), which is appropriate given the company is dispensing FDA-approved branded products and the manufacturer-authored safety language applies directly.

Because Hims primarily dispenses **branded FDA-approved** GLP-1s rather than compounded versions, the compounded-quality concerns relevant at TeleZenMD, Henry, Mochi, and other compounded providers do not apply at the same scale here. This is the most meaningful safety differentiator in Hims's category positioning. (Hair Hybrids and enclomiphene-based testosterone support remain compounded, with the corresponding caveats.)

Asynchronous care is fast and convenient. It is also less interactive than live video for patients who genuinely benefit from real-time clinical conversation. Choose the model that fits your needs.

## The compounding question

Hims's positioning inside the FDA compounding regulatory squeeze is materially different from the compounded-DTC providers we cover elsewhere. The FDA timeline — semaglutide and tirzepatide removed from shortage (Dec 2024 / Feb 2025), 503A and 503B grace periods ending in April and May 2025, the 503B Bulks List exclusion proposal of April 2026, and the public-comment deadline of [29 June 2026](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list "Source — FDA press announcement, Apr 2026") (later [extended to 30 July 2026](https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal "Source — Federal Register, extension of comment period, 26 June 2026"); no final decision as of 7 October 2026) — applies to compounded products. Hims has pivoted heavily out of compounded GLP-1 over the past 18 months and now dispenses these molecules predominantly as **branded FDA-approved** medications via manufacturer-direct partnerships.

The compounded categories where Hims retains exposure are smaller-scale: the Hair Hybrids line (topical finasteride + minoxidil combinations), enclomiphene-based testosterone support, and custom Rx skincare. These are subject to standard 503A compounding regulation, but they're not the subjects of the FDA's GLP-1-specific enforcement push.

For Hims's GLP-1 menu specifically, the regulatory deadline matters less than for compounded competitors — Hims's prescriptions are already on FDA-approved drug labels with manufacturer-supported supply chains.

## The wider menu

Selected entry pricing across Hims's categories:

| Category | Entry price | Notes |
| --- | --- | --- |
| ED treatments | **From $2/dose** with subscription | Sildenafil 20/60/100 mg, tadalafil 3/10/20 mg generics; branded Viagra and Cialis also available |
| Hair regrowth — oral finasteride | From $22/mo | FDA-approved (Propecia, 1997) |
| Hair regrowth — minoxidil serum | From $15/mo | FDA-approved (Rogaine, 1988) |
| Hair regrowth — minoxidil foam | From $19/mo | FDA-approved (Rogaine foam) |
| Hair Hybrids — Rx Hair Loss Spray (topical fin + minox) | From $29/mo | **Compounded** (not FDA-approved) |
| Hair Hybrids — Spray + Ketoconazole + Biotin | From $33/mo | **Compounded** |
| Hair Hybrids — Rx Hair Loss Serum | From $29/mo | **Compounded** |
| Hair Hybrids — Finasteride + Minoxidil + Supplement Blend (pill or chew) | From $29/mo | **Compounded** |
| Minoxidil + Supplement Blend Chew | From $29/mo | **Compounded** |
| Hair Power Pack | From $60/mo | Bundle including compounded |
| Dandruff Detox Shampoo (zinc pyrithione) | From $18/mo | OTC |
| Mental Health — sertraline (Zoloft generic) | Subscription pricing per intake | FDA-approved |
| Mental Health — escitalopram (Lexapro generic) | Subscription pricing per intake | FDA-approved |
| Testosterone support | Subscription pricing per intake | Enclomiphene-based (compounded; not traditional FDA-approved TRT) |
| Lab testing — 130+ biomarker panel | Per-panel pricing | Multi-analyte |
| Cancer-signal test | Per-test pricing | "**Test for a cancer signal is not FDA approved and not diagnostic.**" |

The compounded-versus-FDA-approved mix on the hair page is worth highlighting. FDA-approved oral finasteride and oral minoxidil sit alongside compounded Hair Hybrids in the same visual product grid. The compounded disclosure ("Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Rx required.") appears at the bottom of the page; the per-product badges distinguish "FDA-approved" from "Rx" labels, but a casual scanner could miss the distinction.

## Backed by a named advisory layer

Hims publishes a named medical advisory team prominently on its home page. We cross-checked four of the foregrounded advisors against the public [NPI Registry](https://npiregistry.cms.hhs.gov/ "Source — CMS National Provider Identifier Registry") on 10 June 2026 — all four are individually registered and actively licensed.

On 15 October 2026 the home page featured five doctors: the four above and the Head of Medical Affairs, Brian Williams, MD. Hims gives no specialty or state for him, and the NPI Registry lists well over a hundred physicians of that name, so we could not tie him to a single record.

The cumulative effect is a larger named advisory layer than any compounded-DTC competitor we cover. Whether the advisory layer maps to the patient's actual prescribing visit — a typical Hims weight-loss visit is with one of 400+ network providers, not the foregrounded advisors — is a different question. The advisory roster signals **company-level clinical seriousness** rather than **per-visit physician depth**.

## Pros and cons

**Reading the third-party signals.** Hims sits at an unusual signal mix for the category. The Better Business Bureau lists Hims & Hers Inc. as **accredited, currently not rated**, with a 3.63-out-of-5 customer review average across 5,985 reviews. Trustpilot, by contrast, shows a 2.9/5 rating across 9,743 reviews for Hims, 29% of them one-star ([Trustpilot](https://www.trustpilot.com/review/hims.com "Source — Trustpilot Hims profile, read 9 Nov 2026")) — meaningfully lower than the compounded-DTC operators (Mochi 4.5, Henry 4.3, TeleZenMD 4.5). Different signals, different things measured; the BBB-versus-Trustpilot inversion vs. Henry/Mochi (where BBB customer reviews are weak and Trustpilot strong) is real and worth flagging.

**Pros.**

**BBB-accredited since 2018, currently not rated.** [Hims & Hers Inc.'s BBB business profile](https://www.bbb.org/us/ca/san-francisco/profile/health-and-medical-products/hims-hers-inc-1116-880029 "Source — Better Business Bureau, Hims & Hers Inc. business profile, read 14 October 2026") lists it as a BBB Accredited Business since 21 February 2018 but shows no letter grade: "Not Rated", because BBB "does not have sufficient information". The same profile carries a 3.63-out-of-5 customer review average across 5,985 reviews and 4,511 complaints in the last three years.

**Branded FDA-approved GLP-1 menu.** Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro — all on FDA-approved labels with manufacturer-supported supply.

**Manufacturer pivot worked at the institutional level.** Novo Nordisk filed a lawsuit against Hims in February 2026 alleging unlawful mass-marketing of unapproved compounded semaglutide. On 9 March 2026, [Novo Nordisk dropped the lawsuit](https://investors.hims.com/news/news-details/2026 "Source — Hims & Hers Investor Relations, 9 March 2026 announcement") concurrent with the announcement of a strategic shift: Hims pivoting to selling branded Wegovy through the NovoCare partnership instead. The dispute resolved through a commercial partnership rather than continued litigation — a materially different outcome from the active Eli Lilly cases against the compounded-DTC competitors (Henry Meds, Mochi Health) where lawsuits remain unresolved. Lilly itself followed on 6 November 2026 with [an agreement of its own](https://investors.hims.com/news/news-details/2026/Lilly-and-Hims--Hers-expand-access-to-FDA-approved-Lilly-medicines/default.aspx "Source — Eli Lilly and Hims & Hers joint press release, 6 November 2026"): patients prescribed on the Hims platform pay the same self-pay prices Lilly offers anyone, from $299 a month for Zepbound and $149 for Foundayo, and the two companies state that Hims "has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future." Those are the prices already on the Hims menu, so the agreement formalises the arrangement rather than changing what a patient pays.

**LillyDirect and NovoCare partner pricing** brings the headline med cost down meaningfully ($299/mo Zepbound Vial vs. $1,899/mo full retail). The partner programs are real value when they fit the patient.

**Named advisors who check out.** Four foregrounded medical advisors cross-checked against the NPI Registry; all four are registered and active.

**Outcome claims footnote to peer-reviewed primary trials.** The "up to 25% weight loss" headline cites the Lancet 2025 STEP UP trial; this is the appropriate evidence base, not a self-published retrospective.

**Substantial public-company transparency.** Hims & Hers Health, Inc. files 10-K, 10-Q, 8-K, and other reports with the SEC. Quantitative claims about customer counts, revenue, and operations can be verified against primary financial filings — a transparency option not available at private competitors.

**Asynchronous care model** is fast and convenient for patients who don't want a live video visit.

**Hair regrowth has FDA-approved options.** Oral finasteride and oral minoxidil are listed alongside the compounded Hair Hybrids; patients who want FDA-approved-only can pick from a clean menu.

**Cons and trade-offs.**

**"From $149/mo" understates all-in cost.** The membership ($39 first → $149 recurring) is foregrounded as a footnote, not as a headline number. Patients who calculate Wegovy Pen as "$199/mo" will be off by $149/mo every month after the first.

**Same molecule at two prices on one page.** Tirzepatide appears as $299/mo (Zepbound Vial via LillyDirect) and $1,899/mo (branded full retail) without plain-language explanation. Patients have to know about LillyDirect to understand the gap.

**Trustpilot rating is 2.9/5.** Below the compounded-DTC providers we cover. The sample size (9,743 reviews for Hims) is also smaller than at Henry or Mochi despite Hims's larger subscriber count, suggesting Hims's review-solicitation pattern is less aggressive (or less effective) than at compounded peers.

**The FTC and seven states are suing Hims over privacy and cancellation.** The Federal Trade Commission, the Utah Division of Consumer Protection and Los Angeles County filed suit on 29 July 2026 in the Northern District of California; on 10 November 2026 an [amended complaint](https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices "Source — Federal Trade Commission press release, 10 November 2026") added Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs. The complaint alleges that Hims shared sensitive health information with Meta, Snap and other advertising platforms while promising privacy, that it charges for a prescription almost immediately after the intake form rather than after the promised consultation, and that cancelling a subscription is made difficult — claims brought under Section 5 of the FTC Act, the Restore Online Shoppers' Confidence Act and the seven states' consumer-protection laws. The case is [FTC et al. v. Hims & Hers Health, Inc., No. 3:26-cv-07871-VC](https://www.ftc.gov/legal-library/browse/cases-proceedings/x260029-hims-hers-health-inc-ftc-v "Source — FTC case page, matter X260029, last updated 10 November 2026"), and nothing in it has been decided by the court. Hims filed a motion to dismiss on 22 October 2026, set for hearing on 14 January 2027, and told shareholders it believes it has meritorious arguments and will defend vigorously.

**The company has set aside about $60 million against that case.** Its [Q3 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000246/hims-20260930.htm "Source — Hims & Hers Health, Inc., Form 10-Q for the quarter ended 30 September 2026, filed 9 November 2026") records a legal contingency accrual of approximately $60 million for the FTC matter as of 30 September 2026, and says the figure may move materially in either direction. Two private suits follow the same facts: a privacy class action (Doe v. Hims & Hers Health, Inc.) in the same court, and a securities class action (Velanki v. Hims & Hers Health, Inc., No. 3:26-cv-09313, filed 1 September 2026) on behalf of share purchasers between 4 August 2025 and 29 July 2026. Separately, Australia's Therapeutic Goods Administration has been investigating advertising compliance at subsidiaries of Eucalyptus, which Hims acquired. None of these touch product safety — they are about privacy, billing and disclosure — but the billing and cancellation allegations describe the part of the service a paying reader actually meets.

**Compounded Hair Hybrids share visual space with FDA-approved finasteride.** The compounded disclosure exists at the page bottom; the per-product badges are clear if you read them; the visual product grid does not strongly differentiate.

**MedMatch AI marketed without published clinical validation.** The decision-support tool is described as a clinical capability; no peer-reviewed independent evaluation has been published.

**Asynchronous-by-default care reduces real-time clinical depth.** Faster on average, less interactive than live video for patients who benefit from conversation.

**One featured doctor cannot be matched to a registry record.** Hims gives no specialty or state for its Head of Medical Affairs, Brian Williams, MD, and the name is shared by many registered physicians. The other four featured doctors are verified.

## Who should choose — and skip

Hims makes the most sense for the patient who wants **FDA-approved branded GLP-1 with a named advisory layer**, can budget around the membership-plus-medication structure, and values the option to verify any quantitative claim against Hims & Hers SEC filings. It fits people who'd rather take Wegovy or Zepbound through a partner-direct program than a compounded equivalent, who use multiple categories (GLP-1 + ED + hair + labs) and want one platform for all of them, and who are comfortable with async-by-default care.

Skip it if you are paying out of pocket and a lower monthly price on compounded GLP-1 is the priority — Hims's all-in monthly ($338-$448 typical) is meaningfully higher than the compounded competitors in our set ($178-$278 typical at Mochi or Henry's monthly tier). Skip it if you specifically want live video with your prescribing provider every visit — Hims is async-by-default. Skip it if you want full transparency around AI-assisted clinical decisions — MedMatch is operationally novel but clinically unstudied. And if you want compounded-only hair products (rather than a mix), Hims's Hair Hybrids share the page with FDA-approved finasteride and minoxidil; a competitor with a pure compounded hair line might fit better.

## Hims vs the alternatives

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Hims's position is clear enough at this level.

Against the **other branded-DTC operator** (Ro), Hims offers a similar broad-menu structure, comparable named-advisor depth, and a clearer SEC-filings transparency story. Ro counters with celebrity ambassador presence (Serena Williams, Charles Barkley), a built-in insurance-check tool that Hims doesn't offer, and a private structure that some patients may prefer for privacy reasons. Against the **compounded-DTC operators** (TeleZenMD, Henry, Mochi, TrimRx), Hims is materially more expensive but operates on the cleaner branded-drug evidence base. Against **testosterone-focused competitors** (Maximus), Hims's testosterone offering is narrower (enclomiphene only, no FDA-approved TRT format), but the GLP-1 and broader weight-loss surface is more developed.

The clearest case for Hims over any of those alternatives is wanting FDA-approved branded GLP-1 from a public-company platform with named advisers, with the budget headroom for the membership-plus-medication structure.

## Who makes the medication

From Hims’s public pages, read Sep 24, 2026.

|  |  |
| --- | --- |
| Pharmacy | Names the pharmacy: Apostrophe Pharmacy LLC, XeCare LLC, EHT Pharmacy LLC dba Curexa, CD Pharmacy LLC dba Red Rock Pharmacy, AnazaoHealth Corporation, Strive Specialties, Inc. |
| Prescriber | Names a medical group, no clinicians: You Health professional corporations in Alaska, California, Hawaii, Kansas, Nebraska, Nevada, New Jersey and Texas |

Its terms name six pharmacies and say a prescription may be transferred between them. The terms name the medical groups, not individual clinicians.

Read from: [Hims terms and conditions](https://www.hims.com/terms-and-conditions).

How the other providers we cover answer the same question: [which telehealth providers name their pharmacy](https://peptidewellnessusa.com/learn/which-providers-name-their-pharmacy/).

## Frequently asked

### Is Hims legit?

Hims & Hers Health, Inc. is a publicly traded company on the NYSE (ticker HIMS), with audited annual reports filed with the SEC dating to 2020. The Better Business Bureau lists Hims & Hers Inc. as BBB Accredited since 2018, currently without a letter grade. LegitScript certification (seal ID 11008607).

Four of the foregrounded medical advisors are verified active in the public NPI Registry. The fifth, Head of Medical Affairs Brian Williams, MD, could not be matched to a single NPI record because Hims gives no specialty or state for him. Multiple FDA-approved branded medications are dispensed through legitimate manufacturer-direct programs.

Novo Nordisk's February 2026 lawsuit was dropped in March 2026 as part of a partnership deal in which Hims sells branded Wegovy through NovoCare, and in November 2026 Eli Lilly signed a comparable agreement. What is open is a government case: the FTC and seven states are suing Hims over privacy, billing and cancellation practices, and the company has accrued about $60 million against it. None of the open matters allege that the medicines themselves are unsafe.

### Is Hims being sued?

Yes, and the biggest case is a government one. The Federal Trade Commission sued Hims & Hers on 29 July 2026 in the Northern District of California, joined by the Utah Division of Consumer Protection and Los Angeles County; an amended complaint on 10 November 2026 added Arizona, Florida, Nebraska, Ohio and Wisconsin. The allegations are that Hims shared sensitive health information with Meta, Snap and other advertising platforms while promising privacy, that it charged for prescriptions almost immediately after the intake form instead of after the consultation it advertised, and that cancelling was made difficult — under Section 5 of the FTC Act, the Restore Online Shoppers' Confidence Act and state consumer-protection laws. The case is FTC et al. v. Hims & Hers Health, Inc., No. 3:26-cv-07871-VC, and the court has decided none of it; Hims moved to dismiss on 22 October 2026, with a hearing set for 14 January 2027, and has accrued about $60 million against the matter.

Two private suits track the same facts — a privacy class action (Doe v. Hims & Hers Health, Inc.) and a securities class action (Velanki v. Hims & Hers Health, Inc., No. 3:26-cv-09313, filed 1 September 2026) — and Australia's Therapeutic Goods Administration is investigating advertising compliance at Eucalyptus subsidiaries Hims acquired. The manufacturer dispute is over: Novo Nordisk sued on 9 February 2026 over compounded semaglutide and dropped it on 9 March 2026 as part of the NovoCare partnership. Sources: FTC case page X260029 and its 10 November 2026 press release; Hims & Hers Form 10-Q for the quarter ended 30 September 2026; Novo Nordisk press release (9 February 2026); Hims Investor Relations (9 March 2026).

### How much does Hims cost?

All figures here are from Hims's public weight-loss page; specific medication eligibility is determined at intake. The Hims Weight Loss Membership is **$39 for the first month, $149/month thereafter** (auto-renew). Medication is billed separately on top of the membership: Wegovy Pill or Foundayo Pill or Ozempic Pill from $149/mo; Wegovy Pen or Ozempic injectable from $199/mo; Zepbound Vial or Zepbound KwikPen from $299/mo (via LillyDirect). Full-retail branded Mounjaro or Zepbound is $1,899/mo. All-in monthly is therefore around $338–$448 for the partner-pricing tiers and around $2,048 for full retail.

### Does Hims take insurance?

No. Hims is cash-pay only. FSA/HSA reimbursement is possible after the fact — Hims's FAQ recommends using a credit/debit card and submitting receipts to your FSA/HSA provider.

### Does Hims sell compounded GLP-1?

Largely no, as of June 2026. Hims has pivoted heavily to FDA-approved branded GLP-1 dispensed through manufacturer-direct programs (NovoCare for Novo Nordisk products, LillyDirect for Eli Lilly products). The branded medications on the current menu — Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro — are not compounded.

### Who actually prescribes through Hims?

Hims says its network includes 400+ U.S.-licensed providers across all 50 states. The five doctors featured on the home page (four of them verified in the NPI Registry, plus a Head of Medical Affairs) are advisors and clinical leadership rather than the specific provider who reviews any given intake. A typical patient is reviewed by one of the network providers, not directly by the foregrounded advisors.

### Does Hims offer FDA-approved testosterone?

Hims's testosterone surface is centered on enclomiphene capsules and supplements, not on FDA-approved TRT formats. Patients who specifically want FDA-approved testosterone (cypionate injection, AndroGel topical, KYZATREX oral) will not find them at Hims; Henry Meds offers KYZATREX, and the standard testosterone-focused providers (Maximus is one) carry the broader format range.

### What is MedMatch?

A proprietary AI/ML decision-support tool that Hims launched in 2023, described as helping providers consider treatment options drawn from de-identified platform interaction data. No peer-reviewed independent evaluation of MedMatch's clinical impact has been published.

### Where are Hims's SEC filings?

Hims & Hers Health, Inc. files reports with the SEC under CIK 0001773751. The latest annual report (Form 10-K for fiscal year 2025) was filed on 23 February 2026. All filings are available on EDGAR.

## Methodology & disclaimers

**How we reviewed this.** Pricing, programs, and process details were pulled directly from Hims's public pages in June 2026 (homepage, /weight-loss, /erectile-dysfunction, /hair-loss, /about/the-company). Corporate details — SEC ticker, CIK, HQ, fiscal year, SPAC origin, latest 10-K filing date — were verified against the SEC's EDGAR public filings index.

Prescriber verification was conducted independently against the public [NPI Registry](https://npiregistry.cms.hhs.gov/ "Source — CMS National Provider Identifier Registry") for four of the five doctors featured on the home page — all four individually registered and active. The fifth, Head of Medical Affairs Brian Williams, MD, could not be matched to a single record: Hims gives no specialty or state, and the name is shared by many registered physicians (checked 15 October 2026).

The headline weight-loss claim (up to 25%) is footnoted by Hims to a peer-reviewed primary trial in Lancet Diabetes & Endocrinology (2025); we verified that the citation maps to STEP UP, the higher-dose semaglutide protocol. Standard-dose evidence anchors to STEP 1 (Wilding et al., NEJM 2021). Tirzepatide weight-loss evidence anchors to SURMOUNT-1 (Jastreboff et al., NEJM 2022) and SURMOUNT-5 (Aronne et al., NEJM 2025). Wegovy cardiovascular evidence anchors to SELECT (NEJM 2023). All Tier A peer-reviewed primary trials.

Compounded products in Hair Hybrids, custom Rx skincare, and enclomiphene-based testosterone support are explicitly disclosed by Hims as non-FDA-approved. MedMatch AI is described factually as a company-stated capability without peer-reviewed validation; the public review does not propagate clinical claims about MedMatch.

**Editorial independence.** PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Hims & Hers Health, Inc.

> Editorial note: Informational only — not medical advice. FDA-approved branded medications and compounded medications carry different regulatory and clinical profiles; compounded medications are not FDA-approved. GLP-1, hair, sexual-health, and mental-health treatment decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.